Abcellera Biologics Inc (ABCL)vsAlnylam Pharmaceuticals Inc (ALNY)
ABCL
Abcellera Biologics Inc
$3.39
+2.42%
HEALTHCARE · Cap: $1.03B
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 4843% more annual revenue ($3.71B vs $75.13M). ALNY leads profitability with a 8.5% profit margin vs -1.9%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ABCL
Hold41
out of 100
Grade: D
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABCL.
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Earnings expanding 45.9% YoY
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
Smaller company, higher risk/reward
ROE of -14.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Price/Book, Debt/Equity, EPS Growth.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ABCL
The primary concerns for ABCL are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
ABCL profiles as a turnaround stock while ALNY is a hypergrowth play — different risk/reward profiles.
ABCL carries more volatility with a beta of 0.87 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 41/100) and 84.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?